Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia

Neuroscience Letters

Volumn 502, Issue 3, 2011, Pages 143-146

  Francesconi, L P ^a   Cereser K M ^a,b   Mascarenhas, R ^a   Stertz, L ^b   Gama, C S ^a,b   Belmonte de Abreu, P ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Annexin V; Inflammation; Schizophrenia; TNF

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LIPOCORTIN 5; PIMOZIDE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGGRESSION; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ANNEXIN A5; ANTIPSYCHOTIC AGENTS; BRAIN; CHRONIC DISEASE; DOWN-REGULATION; ENERGY METABOLISM; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 80052348076     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.06.042     Document Type: Article

References (34)

1. Abbas N., Zou L.P., Pelidou S.H., Winblad B., Zhu J. Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system. Autoimmunity 2000, 2:93-99.
2. Banday A.A., Lokhandwala M.F. Oxidative stress reduces renal dopamine D receptor-Gq/11alpha G protein-phospholipase C signaling involving G protein-coupled receptor kinase 2. Am. J. Physiol. Renal. Physiol. 2007, 293:306-315.
3. Berger G.E., Wood S., Mcgorry P.D. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol. Bull. 2003, 37:79-101.
4. Berk M., Plein H., Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci. 2000, 66:2427-2432.
5. Berk M., Plein H., Csizmadia T. Supersensitive platelet glutamate receptors as a possible peripheral marker in schizophrenia. Int. Clin. Psychopharmacol. 1999, 14:119-122.
6. Craddock M., Asherson P., Owen M.J., Williams J., McGuffin P., Farmer A.E. Concurrent validity of the OPCRIT diagnostic system, comparison of OPCRIT diagnoses with consensus best-estimate lifetime diagnoses. Br. J. Psychiatry 1996, 169:58-63.
7. A.S. Damaso, Análise gênica e protéica da anexina 1 na biologia do desenvolvimento e na fisiopatologia da inflamação, Tese de Doutorado, Universidade Federal de São Paulo, Escola Paulista de Medicina, 2006.
8. Edwards H.C., Crumpton M.J. Ca dependent phospholipids and arachidonic acid binding by the placental annexins VI and IV. Eur. J. Biochem. 1991, 198:121-129.
9. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 2003, 348:1365-1375.
10. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 2007, 420:45-48.
11. Gama C.S., Berk M., Andreazza A.C., Kapczinski F., Belmonte-de-Abreu P. Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Rev. Bras. Psiquiatria 2008, 30:337-340.
12. Gama C.S., Salvador M., Andreazza A.C., Lobato M.I., Berk M., Kapczinski F., Belmonte-de-Abreu P.S. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 2008, 433:270-273.
13. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Silva P., Belmonte-de-Abreu Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:512-515.
14. Grignon S., Chianetta J.M. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:365-369.
15. Huber R., Berendes R., Burger A., Lucked H., Karshikov A. Annexin V-crystal structure and its implications on function. Behring Inst. Mitt. 1992, 91:107-125.
16. Kalinichenko S.G., Matveeva N.Y. Morphological characteristics of apoptosis and its significance in neurogenesis. Neurosci. Behav. Physiol. 2008, 38:333-344.
17. Kato T., Monji A., Hashioka S., Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 2007, 92:108-115.
18. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Ceresér K.M., Gomes F.A., Belmonte-de-Abreu P.S., Berk M., Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1677-1681.
19. M. Kunz, K.M. Ceresér, P.D. Goi, G.R. Fries, A.L. Teixeira, B.S. Fernandes, P.S. Belmonte-de-Abreu, M. Kauer-Sant'anna, F. Kapczinski, C.S. Gama, Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance, Rev. Bras. Psiquiatria (2011), pii: S1516-44462011005000009 (Epub ahead of print).
20. López-Gil X., Babot Z., Amargós-Bosch M., Suñol C., Artigas F., Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32:2087-2097.
21. Marder S.R., Mintz J., Van Putten T., Lebell M., Wirshing W.C., Johnston-Cronk K. Early prediction of relapse in schizophrenia: an application of receiver operating characteristic (ROC) methods. Psychopharmacol. Bull. 1991, 27:79-82.
22. Mizutani A., Tokumitsu H., Kobayashi R., Hidaka H. Phosphorylation of annexin XI (CAP-50) in SR-3Y1 cells. J. Biol. Chem. 1993, 268:1517-1522.
23. Pedrini M., Chendo I., Grande I., Lobato M.I., Belmonte-de-Abreu P.S., Lersch C., Walz J., Kauer-Sant'anna M., Kapczinski F., Gama C.S. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positivecorrelation. Neurosci. Lett. 2011, 491:207-210.
24. Pollard H.B., Rojas E. Ca2+-activated synexin forms highly selective, voltage-gated Ca2+ channels in phosphatidylserine bilayer membranes. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:2974-2978.
25. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
26. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., Tkachev D., Mimmack M.L., Yolken R.H., Webster M.J., Torrey E.F., Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9:684-697.
27. Reutelingsperger C.P., van Heerde W.L. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell. Mol. Life Sci. 1997, 53:527-532.
28. Romano F., Elkis H. Tradução e Adaptação de um Instrumento de Avaliação Psicopatológica das Psicoses: a Escala Breve de Avaliação Psiquiátrica, Versão Ancorada (BPRS-A). J. Bras. Psiquiatria 1996, 45:43-49.
29. Ross B.M. Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69:407-412.
30. Rothermundt M., Arolt V., Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 2001, 15:319-339.
31. Shao L., Martin M.V., Watson S.J., Schatzberg A., Akil H., Myers R.M., Jones E.G., Bunney W.E., Vawter M.P. Mitochondrial involvement in psychiatric disorders. Ann. Med. 2008, 40:281-295. (Review).
32. Takeuchi H., Jin S., Wang J., Zhang G., Kawanokuchi J., Kuno R., Sonobe Y., Mizuno T., Suzumura A. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 2006, 281:21362-21368.
33. Vargas H.E., Gama C.S., Andreazza A.C., Medeiros D., Stertz L., Fries G., Palha J., Ceresér K.M., Berk M., Kapczinski F., Belmonte-de-Abreu P.S. Decreased serum neurotrophin 3 in chronically medicated schizophrenic males. Neurosci. Lett. 2008, 440:197-201.
34. Wood S.J., Yücel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann. Acad. Med. Singapore 2009, 38:396. (Review).